KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Invested Capital: 2010-2024

Historic Invested Capital for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $1.1 billion.

  • Supernus Pharmaceuticals' Invested Capital rose 0.68% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 0.68%. This contributed to the annual value of $1.1 billion for FY2024, which is 11.25% up from last year.
  • Supernus Pharmaceuticals' Invested Capital amounted to $1.1 billion in FY2024, which was up 11.25% from $973.6 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Invested Capital peaked at $1.2 billion during FY2021, and registered a low of $775.8 million during FY2020.
  • Moreover, its 3-year median value for Invested Capital was $973.6 million (2023), whereas its average is $988.0 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Invested Capital spiked by 54.06% in 2021 and then declined by 24.08% in 2022.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Invested Capital stood at $775.8 million in 2020, then spiked by 54.06% to $1.2 billion in 2021, then declined by 24.08% to $907.3 million in 2022, then rose by 7.30% to $973.6 million in 2023, then climbed by 11.25% to $1.1 billion in 2024.